Factors affecting chlorpromazine plasma levels in psychiatric patients.
about
Clinical significance of pharmacokinetic interactions between antiepileptic and psychotropic drugs.Destruction of chlorpromazine during absorption in the rat in vivo and in vitroDestruction of chlorpromazine during absorption by rat intestine in vitroLithium kinetics in man: effect of variation in dosage pattern.Chlorpromazine: concentrations in plasma, excretion in urine and duration of effectClinical utility of drug measurement and pharmacokinetics: therapeutic drug monitoring in psychiatry.Cytochrome P-450 monooxygenases and interactions of psychotropic drugs.The assay of chlorpromazine and metabolites in blood, urine, and other tissues.Drug treatment in schizophrenia.The clinical implications of first-pass metabolism: treatment strategies for the 1990s.Clinical effects and drug concentrations in plasma and cerebrospinal fluid in psychotic patients treated with fixed doses of chlorpromazine.Metabolic inhibition in primary cell cultures by lipid-soluble molecules.Theoretical changes in drug distribution resulting from changes in binding to plasma proteins and to tissues.Chlorpromazine metabolism. IX. Pharmacokinetics of chlorpromazine following oral administration in man.Neuroleptic blood levels and clinical response.A simple and sensitive radioreceptor assay for antischizophrenic drugs in blood.Trial of maintenance therapy in schizophrenia.Epidemiology of acute drug intoxications: patient characteristics, drugs, and medical complications.Controlled Trial of Penfluridol in Acute Psychosis.
P2860
Q34119454-87D51B71-6220-477F-8439-ECC8AFECE6F5Q35173763-A034D7B5-B136-4ED9-964C-78C7A48D3CA9Q35226509-2FCB783E-45E0-4367-B6A2-7F25407C561EQ35600550-7D60AA4B-9CBD-42E5-95DB-50F5E54D3762Q35665766-BECA7A30-CFCA-4DDE-85A1-5B0691353E66Q37057313-0C918737-4060-438E-81B5-D1ABB3530CFDQ37775963-EC2F640B-04AF-4102-BFE5-71D323797325Q40003788-366DB56B-990B-4248-B008-F4CC47F8563DQ40006478-7D72B854-219B-49BB-A3F0-337BA4EA5E04Q40843468-1C783F14-CD75-4CD7-9815-A2860B2BE686Q40940702-22011454-09E4-48D2-B37E-C852FD62B549Q41338830-B1158DB0-C149-473C-9C74-439A2699F405Q43898201-3E027098-CC62-454F-BFB9-65187CFA3C31Q45060464-EB41472E-0B5A-4B8B-9EEA-DB0FA9368D29Q47598657-A427DB86-0D40-4E42-8E5B-5229F1E6A33EQ48251559-4B33A9EF-0A5F-47F2-8392-110031EB8AAFQ53794512-DA131F50-25E1-406E-B5C6-C15FB84AC158Q54525919-BF97A90E-7C3A-49D0-BFD4-D323E3488318Q55118841-10D69317-EA0F-4D8A-9E74-3F1CB9B42685
P2860
Factors affecting chlorpromazine plasma levels in psychiatric patients.
description
1970 nî lūn-bûn
@nan
1970年の論文
@ja
1970年学术文章
@wuu
1970年学术文章
@zh
1970年学术文章
@zh-cn
1970年学术文章
@zh-hans
1970年学术文章
@zh-my
1970年学术文章
@zh-sg
1970年學術文章
@yue
1970年學術文章
@zh-hant
name
Factors affecting chlorpromazine plasma levels in psychiatric patients.
@en
Factors affecting chlorpromazine plasma levels in psychiatric patients.
@nl
type
label
Factors affecting chlorpromazine plasma levels in psychiatric patients.
@en
Factors affecting chlorpromazine plasma levels in psychiatric patients.
@nl
prefLabel
Factors affecting chlorpromazine plasma levels in psychiatric patients.
@en
Factors affecting chlorpromazine plasma levels in psychiatric patients.
@nl
P2093
P1433
P1476
Factors affecting chlorpromazine plasma levels in psychiatric patients.
@en
P2093
P304
P356
10.1001/ARCHPSYC.1970.01740270017002
P407
P577
1970-03-01T00:00:00Z